Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Item

http://www.wikidata.org/entity/Q31089499

Q31089499

about

Trastuzumab containing regimens for early breast cancer Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Breast cancer chemoprevention: old and new approaches Neoadjuvant therapy in the treatment of breast cancer Twenty years of anti-HER2 therapy-associated cardiotoxicity Treatment of early-stage HER2+ breast cancer-an evolving field Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Translating neoadjuvant therapy into survival benefits: one size does not fit all.Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.Proteomics, morphoproteomics, saliva and breast cancer: an emerging approach to guide the delivery of individualised thermal therapy, thermochemotherapy and monitor therapy response.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma Targeted Therapy for Early and Locally Advanced Breast Cancer NEO adjuvant chemotherapy in breast cancer: What have we learned so far?Targeting HER2 in breast cancer: overview of long-term experience Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience.Testing for HER2 in Breast Cancer: A Continuing Evolution.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm?Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.Current neoadjuvant treatment options for HER2-positive breast cancer.Targeting the HER/EGFR/ErbB family to prevent breast cancer.Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Review of breast conservation therapy: then and now Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study Pre-operative systemic therapy in locally advanced breast cancer: a single institution experience.

P2860

Q24200192-DE0AA511-B9D0-4F5A-81F1-1B8485CEADB3 Q26752024-30009394-5805-41AD-94B9-F6B02BB6910A Q27001729-FFA72BB9-0D02-4937-9583-310B9C16F9C9 Q27025863-A132825F-399D-40A5-AEF2-83B28479A5FC Q27693259-E7CD9346-CCD2-47DB-91AD-8845366B9FFE Q27694514-749FAA99-8E98-40A3-B59E-1F124CE294E8 Q28079391-C307BB1E-B6CA-4718-B7F8-D774D1C3C019 Q28081124-D5DAFE2D-CF8D-4507-898A-20503FA372AA Q28260063-485A5E21-D35C-4FDF-80DF-9DA14757360D Q30249335-FF3BB917-9966-4915-984C-7FBFEB335D7F Q30251738-51AEC03F-D74F-4586-B145-1DBF39724831 Q30433483-990411C5-C933-473F-9554-AADFA32B7E2C Q33407805-E36BEAAF-45C5-4D34-A8B4-0493BB04B195 Q33668173-98E1A289-E815-4876-9267-F813FCA96D3D Q33694698-1BF888F7-80AF-495E-AEC7-3BDDABA6CD8A Q33698446-96CDF428-58CC-427A-8D14-3C87D23F6DB9 Q33711632-14E78B67-B1D6-479A-825A-E3AA522933F2 Q33739253-E6D81536-EBE7-4798-A89D-BF0FBD2CAC30 Q34023704-65F6D423-3291-4BA5-BB08-B6D9FD180CA5 Q34042715-A2F1F738-B392-42B0-8A89-2FACF6CA4294 Q34059719-18D3B5CE-EE75-46B3-841A-1EE2E09EA131 Q34064466-78167726-D79B-462E-81A8-BFE712F58330 Q34096070-31322DB2-3BF1-42B7-B6E3-BC754860621C Q34138174-23AB4EF7-0298-48F0-9767-609810719C7E Q34272044-7B644B3A-70DA-4949-AF47-C15C22E84FA7 Q34344198-C802527C-361D-4B63-BB2C-8EA6BA1B1FFF Q34403544-AF3218DC-D2C0-42A3-8A18-1627578C73EA Q34424285-C831E169-CE73-42E3-94F7-C5E1068FDEB0 Q34996054-940D3544-98FA-4B7E-AA70-870FE9CE18BC Q35018233-528BF05D-1110-4F93-B6EB-AD724AED2B5D Q35023486-1AF3CBB8-0081-455C-940B-8DEB708C7BB3 Q35072438-669DDF0C-969C-4920-99B6-43F2DD2836BE Q35087084-0CE11114-DFBF-47F8-AB09-2ED4D93ECE4E Q35098320-7ABF6CCD-6DF2-414D-A191-2B017111209D Q35164938-EF473C60-E846-42B5-BE58-30A9ADB25E0B Q35208654-59FD5DDA-7ED0-4D04-8426-51287F063AE6 Q35238008-B9457E23-F7B6-4944-9A11-2BA2851701DB Q35433289-632BD720-5B65-420F-84BC-11D8F680D508 Q35539538-30B5CAC5-6A11-4382-8AED-53FF7D403501 Q35572926-5AB4AA11-2AFB-4FAA-99DE-69F2565C4415

P2860

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

Item

http://www.wikidata.org/entity/Q31089499

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu